Artificial Retinal Implants Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The artificial retinal implants market encompasses surgically implanted visual prostheses that electrically stimulate remaining retinal neurons to provide functional vision to blind patients with end-stage retinal degeneration. The Argus II Retinal Prosthesis System, developed by Second Sight Medical Products, received FDA approval in 2011 and became the first commercially available bionic vision device, with clinical deployments across the United States, Europe, and other regions.

• •The market is valued at approximately $0.4 billion in 2025 with an 8.5% annual growth rate
• •Major commercial devices include the Argus II (epiretinal) and PRIMA (subretinal) systems
• •Primary target patient populations are those with advanced retinitis pigmentosa and dry age-related macular degeneration

The rising global incidence of retinal degenerative diseases, particularly among aging demographics, creates a growing addressable patient population that currently lacks effective treatment options beyond assistive devices. Advances in microelectrode array design, flexible biocompatible substrates, and low-power processing algorithms are improving the visual acuity, safety, and longevity of next-generation implants, expanding their clinical utility.

• •Growing elderly population increases prevalence of dry AMD and retinitis pigmentosa worldwide
• •Technological improvements in flexible sensors, microelectrode density, and power efficiency enhance device performance
• •Regulatory approvals and accumulated clinical experience build clinician and patient confidence in implant therapies

The market is segmented by implant type into epiretinal devices, which sit on the inner retinal surface, and subretinal devices, which are positioned beneath the retina. Geographically, North America and Europe dominate current commercial activity due to established regulatory pathways and early adoption of novel ophthalmic technologies, while the Asia-Pacific region is emerging as a high-growth market.

• •Epiretinal systems such as Argus II and IRIS II represent the currently commercialized segment, while subretinal platforms like PRIMA are advancing through clinical trials
• •North America and Europe lead in market share owing to FDA and CE-mark approvals and broader reimbursement frameworks
• •Asia-Pacific is expected to register faster growth rates driven by improving healthcare infrastructure and rising disease burden

What are the recent trends and outlook?

Future product development is focused on increasing electrode channel counts to improve visual acuity, integrating AI-powered image processing for scene interpretation, and developing fully implantable wireless systems to reduce external hardware. Patient preference studies indicate strong demand for devices that deliver meaningful visual perceptions and improve daily mobility, supporting continued investment in bionic vision technologies through 2030 and beyond.

• •Next-generation implants are targeting higher electrode resolutions and machine-learning-based visual processing to deliver more functional vision
• •Patient acceptability and quality-of-life metrics are becoming central to clinical evaluation and market adoption
• •Long-term clinical follow-up data is accumulating, informing device refinements and supporting expanded regulatory indications